

7. BIBLIOGRAFIA

1. Boyle, P. and Ferlay, J. (2005). Cancer incidence and mortality in Europe, 2004. *Ann Oncol* **16**, 481-488.
2. Cahill, D. P., Kinzler, K. W., Vogelstein, B., and Lengauer, C. (1999). Genetic instability and darwinian selection in tumours. *Trends Cell Biol* **9**, M57-M60.
3. Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. *Cell* **100**, 57-70.
4. Skobe, M. and Fusenig, N. E. (1998). Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. *Proc Natl Acad Sci U S A* **95**, 1050-1055.
5. Soussi, T. and Lozano, G. (2005). p53 mutation heterogeneity in cancer. *Biochem Biophys. Res Commun.* **331**, 834-842.
6. Kirkin, V., Joos, S., and Zornig, M. (2004). The role of Bcl-2 family members in tumorigenesis. *Biochim. Biophys. Acta* **1644**, 229-249.
7. Fresno Vara, J. A., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., and Gonzalez-Baron, M. (2004). PI3K/Akt signalling pathway and cancer. *Cancer Treat. Rev* **30**, 193-204.
8. Shay, J. W. and Bacchetti, S. (1997). A survey of telomerase activity in human cancer. *Eur J Cancer* **33**, 787-791.
9. Perez-Atayde, A. R., Sallan, S. E., Tedrow, U., Connors, S., Allred, E., and Folkman, J. (1997). Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. *Am J Pathol* **150**, 815-821.
10. Folkman, J. (1992). The role of angiogenesis in tumor growth. *Semin Cancer Biol* **3**, 65-71.
11. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? *J Natl Cancer Inst* **82**, 4-6.
12. Rofstad, E. K. and Danielsen, T. (1999). Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. *Br. J. Cancer* **80**, 1697-1707.
13. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol* **146**, 1029-1039.
14. Fox, S. B. (1997). Tumour angiogenesis and prognosis. *Histopathology* **30**, 294-301.
15. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci U S A* **91**, 4082-4085.
16. Mori, S., Ueda, T., Kuratsu, S., Hosono, N., Izawa, K., and Uchida, A. (1995). Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. *Int J Cancer* **61**, 148-152.
17. Weinstat-Saslow, D. L., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., and Steeg, P. S. (1994). Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. *Cancer Res* **54**, 6504-6511.
18. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* **88**, 277-285.
19. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, N. R., Crystal, R. G., Moore, M. A., Hajjar, K. A., Manova, K., Benezra, R., and Rafii, S. (2001). Impaired recruitment of bone-marrow-derived

- endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nat Med* **7**, 1194-1201.
20. Hendrix, M. J. C., Seftor, E. A., Hess, A. R., and Seftor, R. E. B. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. *Nat.Med.* **3**, 411-421. 2003.
Ref Type: Generic
21. Conway, E. M., Collen, D., and Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. *Cardiovasc.Res* **49**, 507-521.
22. Bergersm, G. and Benjamin, L. E. Tumorigenesis and the angiogenic switch. *Nat.Med.* **3**, 401-410. 2003.
Ref Type: Generic
23. Ausprunk, D. H. and Folkman, J. (1977). Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. *Microvasc.Res* **14**, 53-65.
24. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., and McDonald, D. M. (2002). Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. *Am J Pathol* **160**, 985-1000.
25. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., and Jain, R. K. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A* **95**, 4607-4612.
26. Jakeman, L. B., Armanini, M., Phillips, H. S., and Ferrara, N. (1993). Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. *Endocrinology* **133**, 848-859.
27. Senger, D. R., Van de, W. L., Brown, L. F., Nagy, J. A., Yeo, K. T., Yeo, T. K., Berse, B., Jackman, R. W., Dvorak, A. M., and Dvorak, H. F. (1993). Vascular permeability factor (VPF, VEGF) in tumor biology. *Cancer Metastasis Rev* **12**, 303-324.
28. Achen, M. G. and Stacker, S. A. (1998). The vascular endothelial growth factor family; proteins which guide the development of the vasculature. *Int J Exp Pathol* **79**, 255-265.
29. Tammela, T., Enholm, B., Alitalo, K., and Paavonen, K. (2005). The biology of vascular endothelial growth factors. *Cardiovascular Research* **65**, 550-563.
30. Korhonen, J., Partanen, J., Armstrong, E., Vaahtokari, A., Elenius, K., Jalkanen, M., and Alitalo, K. (1992). Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. *Blood* **80**, 2548-2555.
31. Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., and Yancopoulos, G. D. (1996). Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. *Cell* **87**, 1161-1169.
32. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly, T. J., Davis, S., Sato, T. N., and Yancopoulos, G. D. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* **277**, 55-60.
33. Valenzuela, D. M., Griffiths, J. A., Rojas, J., Aldrich, T. H., Jones, P. F., Zhou, H., McClain, J., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Huang, T., Papadopoulos, N., Maisonpierre, P. C., Davis, S., and Yancopoulos, G. D. (1999). Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. *Proc Natl Acad Sci U S A* **96**, 1904-1909.
34. Papapetropoulos, A., Fulton, D., Mahboubi, K., Kalb, R. G., O'Connor, D. S., Li, F., Altieri, D. C., and Sessa, W. C. (2000). Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway. *J.Biol.Chem.* **275**, 9102-9105.

35. Zhang, L., Yang, N., Park, J. W., Katsaros, D., Fracchioli, S., Cao, G., O'Brien-Jenkins, A., Randall, T. C., Rubin, S. C., and Coukos, G. (2003). Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. *Cancer Res* **63**, 3403-3412.
36. Xu, Y., Liu, Y. J., and Yu, Q. (2004). Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. *Cancer Res* **64**, 6119-6126.
37. Yamakawa, M., Liu, L. X., Date, T., Belanger, A. J., Vincent, K. A., Akita, G. Y., Kuriyama, T., Cheng, S. H., Gregory, R. J., and Jiang, C. (2003). Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. *Circ Res* **93**, 664-673.
38. Friesel, R. E. and Maciag, T. (1995). Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. *FASEB J* **9**, 919-925.
39. Schreiber, A. B., Winkler, M. E., and Derynck, R. (1986). Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. *Science* **232**, 1250-1253.
40. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., and Nuseir, N. (1987). Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. *Nature* **329**, 630-632.
41. Moghaddam A. Thymidine phosphorylase/platelet endothelial cell derived growth factor: an angiogenic enzyme. *Tumor Angiogenesis*, Oxford University Press , 251-260. 1997. Ref Type: Generic
42. Hu, G., Riordan, J. F., and Vallee, B. L. (1994). Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. *Proc Natl Acad Sci U S A* **91**, 12096-12100.
43. Desbaillets, I., Diserens, A. C., Tribolet, N., Hamou, M. F., and Van Meir, E. G. (1997). Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. *J Exp Med* **186**, 1201-1212.
44. Gullino, P. M. (1995). Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. *Acta Oncol* **34**, 439-441.
45. Kull, F. C., Jr., Brent, D. A., Parikh, I., and Cuatrecasas, P. (1987). Chemical identification of a tumor-derived angiogenic factor. *Science* **236**, 843-845.
46. Sierra-Honigmann, M. R., Nath, A. K., Murakami, C., Garcia-Cardena, G., Papapetropoulos, A., Sessa, W. C., Madge, L. A., Schechner, J. S., Schwabb, M. B., Polverini, P. J., and Flores-Riveros, J. R. (1998). Biological Action of Leptin as an Angiogenic Factor. *Science* **281**, 1683-1686.
47. Nyberg, P., Xie, L., and Kalluri, R. (2005). Endogenous inhibitors of angiogenesis. *Cancer Res* **65**, 3967-3979.
48. Lartigau, E., Le Ridant, A. M., Lambin, P., Weeger, P., Martin, L., Sigal, R., Lusinchi, A., Lubinski, B., Eschwege, F., and Guichard, M. (1993). Oxygenation of head and neck tumors. *Cancer* **71**, 2319-2325.
49. Lartigau, E., Randrianarivelo, H., Avril, M. F., Margulis, A., Spatz, A., Eschwege, F., and Guichard, M. (1997). Intratumoral oxygen tension in metastatic melanoma. *Melanoma Res* **7**, 400-406.
50. Zygunt, A., Tedesco, V. C., Udho, E., and Krucher, N. A. (2002). Hypoxia stimulates p16 expression and association with cdk4. *Exp. Cell Res* **278**, 53-60.
51. Gardner, L. B., Li, Q., Park, M. S., Flanagan, W. M., Semenza, G. L., and Dang, C. V. (2001). Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression. *J. Biol. Chem.* **276**, 7919-7926.

52. To, K. K., Koshiji, M., Hammer, S., and Huang, L. E. (2005). Genetic instability: the dark side of the hypoxic response. *Cell Cycle* **4**, 881-882.
53. Dong, Z., Wang, J. Z., Yu, F., and Venkatachalam, M. A. (2003). Apoptosis-Resistance of Hypoxic Cells: Multiple Factors Involved and a Role for IAP-2. *Am J Pathol* **163**, 663-671.
54. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and Dewhirst, M. W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. *Cancer Res* **56**, 941-943.
55. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* **359**, 843-845.
56. Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., and Gallick, G. E. (2005). HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. *Oncogene* **24**, 3110-3120.
57. Shie, J. L., Wu, G., Wu, J., Liu, F. F., Laham, R. J., Oettgen, P., and Li, J. (2004). RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. *J Biol Chem* **279**, 25010-25016.
58. Mizukami, Y., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., and Chung, D. C. (2004). Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer. *Cancer Res* **64**, 1765-1772.
59. White, F. C., Carroll, S. M., and Kamps, M. P. (1995). VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. *Growth Factors* **12**, 289-301.
60. Gerber, H. P., Condorelli, F., Park, J., and Ferrara, N. (1997). Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes. Flt-1, BUT NOT Flk-1/KDR, IS UP-REGULATED BY HYPOXIA. *J.Biol.Chem.* **272**, 23659-23667.
61. Ozawa, K., Tsukamoto, Y., Hori, O., Kitao, Y., Yanagi, H., Stern, D. M., and Ogawa, S. (2001). Regulation of Tumor Angiogenesis by Oxygen-regulated Protein 150, an Inducible Endoplasmic Reticulum Chaperone. *Cancer Res* **61**, 4206-4213.
62. Abdulmalek, K., Ashur, F., Ezer, N., Ye, F., Magder, S., and Hussain, S. N. (2001). Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. *Am.J.Physiol Lung Cell Mol Physiol* **281**, L582-L590.
63. Hartmann, A., Kunz, M., Kostlin, S., Gillitzer, R., Toksoy, A., Brocker, E. B., and Klein, C. E. (1999). Hypoxia-induced Up-Regulation of Angiogenin in Human Malignant Melanoma. *Cancer Res* **59**, 1578-1583.
64. Griffiths, L., Dachs, G. U., Bicknell, R., Harris, A. L., and Stratford, I. J. (1997). The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. *Cancer Res* **57**, 570-572.
65. Kitazono, M., Takebayashi, Y., Ishitsuka, K., Takao, S., Tani, A., Furukawa, T., Miyadera, K., Yamada, Y., Aikou, T., and Akiyama, S. (1998). Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. *Biochem Biophys.Res Commun.* **253**, 797-803.
66. Chen, E. Y., Mazure, N. M., Cooper, J. A., and Giaccia, A. J. (2001). Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. *Cancer Res* **61**, 2429-2433.

67. Graham, C. H., Forsdike, J., Fitzgerald, C. J., and Macdonald-Goodfellow, S. (1999). Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. *Int J Cancer* **80**, 617-623.
68. Ridgway, P. F., Ziprin, P., Alkhamesi, N., Paraskeva, P. A., Peck, D. H., and Darzi, A. W. (2005). Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro. *J Surg. Res* **124**, 180-186.
69. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H. J., Benedict, W., and Bouck, N. P. (1999). Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis. *Science* **285**, 245-248.
70. Wu, P., Yonekura, H., Li, H., Nozaki, I., Tomono, Y., Naito, I., Ninomiya, Y., and Yamamoto, H. (2001). Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes. *Biochem. Biophys. Res Commun.* **288**, 1149-1154.
71. Cummins, E. P. and Taylor, C. T. (2005). Hypoxia-responsive transcription factors. *Flugers Arch.* **450**, 363-371.
72. Abate, C., Patel, L., Rauscher, F. J., III, and Curran, T. (1990). Redox regulation of fos and jun DNA-binding activity in vitro. *Science* **249**, 1157-1161.
73. Ausserer, W. A., Bourrat-Floeck, B., Green, C. J., Laderoute, K. R., and Sutherland, R. M. (1994). Regulation of c-jun expression during hypoxic and low-glucose stress. *Mol Cell Biol* **14**, 5032-5042.
74. Fantozzi, I., Zhang, S., Platoshyn, O., Remillard, C. V., Cowling, R. T., and Yuan, J. X. J. (2003). Hypoxia increases AP-1 binding activity by enhancing capacitative Ca²⁺ entry in human pulmonary artery endothelial cells. *Am J Physiol Lung Cell Mol Physiol* **285**, L1233-L1245.
75. Laderoute, K. R. (2005). The interaction between HIF-1 and AP-1 transcription factors in response to low oxygen. *Semin Cell Dev Biol* **16**, 502-513.
76. Marden, N. Y., Fiala-Beer, E., Xiang, S. H., and Murray, M. (2003). Role of activator protein-1 in the down-regulation of the human CYP2J2 gene in hypoxia. *Biochem J* **373**, 669-680.
77. May, M. J. and Ghosh, S. (1998). Signal transduction through NF-kappa B. *Immunol Today* **19**, 80-88.
78. Koong, A. C., Chen, E. Y., Mivechi, N. F., Denko, N. C., Stambrook, P., and Giaccia, A. J. (1994). Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). *Cancer Res* **54**, 5273-5279.
79. Toledano, M. B. and Leonard, W. J. (1991). Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. *Proc Natl Acad Sci U S A* **88**, 4328-4332.
80. Aggarwal, B. B., Takada, Y., Shishodia, S., Gutierrez, A. M., Oommen, O. V., Ichikawa, H., Baba, Y., and Kumar, A. (2004). Nuclear transcription factor NF-kappa B: role in biology and medicine. *Indian J Exp Biol* **42**, 341-353.
81. Rahmani, M., Peron, P., Weitzman, J., Bakiri, L., Lardeux, B., and Bernuau, D. (2001). Functional cooperation between JunD and NF-kappaB in rat hepatocytes. *Oncogene* **20**, 5132-5142.
82. Miki, N., Ikuta, M., and Matsui, T. (2004). Hypoxia-induced Activation of the Retinoic Acid Receptor-related Orphan Receptor {alpha}4 Gene by an Interaction between Hypoxia-inducible Factor-1 and Sp1. *J. Biol. Chem.* **279**, 15025-15031.
83. Petrella, B. L., Lohi, J., and Brinckerhoff, C. E. (2005). Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. *Oncogene* **24**, 1043-1052.

84. Xu, Q., Ji, Y. S., and Schmedtje, J. F., Jr. (2000). Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure. *J Biol Chem.* **275**, 24583-24589.
85. Lichtlen, P. and Schaffner, W. (2001). The "metal transcription factor" MTF-1: biological facts and medical implications. *Swiss.Med Wkly.* **131**, 647-652.
86. Cai, L., Satoh, M., Tohyama, C., and Cherian, M. G. (1999). Metallothionein in radiation exposure: its induction and protective role. *Toxicology* **132**, 85-98.
87. van Lookeren, C. M., Thibodeaux, H., van Bruggen, N., Cairns, B., Gerlai, R., Palmer, J. T., Williams, S. P., and Lowe, D. G. (1999). Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. *Proc Natl Acad Sci U S A* **96**, 12870-12875.
88. Lazo, J. S., Kondo, Y., Dellapiazza, D., Michalska, A. E., Choo, K. H., and Pitt, B. R. (1995). Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes. *J Biol Chem.* **270**, 5506-5510.
89. Murphy, B. J., Andrews, G. K., Bittel, D., Discher, D. J., McCue, J., Green, C. J., Yanovsky, M., Giaccia, A., Sutherland, R. M., Laderoute, K. R., and Webster, K. A. (1999). Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. *Cancer Res* **59**, 1315-1322.
90. Murphy, B. J., Sato, B. G., Dalton, T. P., and Laderoute, K. R. (2005). The metal-responsive transcription factor-1 contributes to HIF-1 activation during hypoxic stress. *Biochem Biophys.Res Commun.*
91. McCluggage, W. G., Maxwell, P., Hamilton, P. W., and Jasani, B. (1999). High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. *Histopathology* **34**, 51-55.
92. Greijer, A. E., van der, G. P., Kemming, D., Shvarts, A., Semenza, G. L., Meijer, G. A., van de Wiel, M. A., Belien, J. A., van Diest, P. J., and Van Der, W. E. (2005). Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). *J Pathol* **206**, 291-304.
93. Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., and Maity, A. (2001). Regulation of glut1 mRNA by Hypoxia-inducible Factor-1. INTERACTION BETWEEN H-ras AND HYPOXIA. *J.Biol.Chem.* **276**, 9519-9525.
94. Minchenko, A., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V., and Caro, J. (2002). Hypoxia-inducible Factor-1-mediated Expression of the 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) Gene. ITS POSSIBLE ROLE IN THE WARBURG EFFECT. *J.Biol.Chem.* **277**, 6183-6187.
95. Acker, T. and Plate, K. H. (2002). A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. *J.Mol.Med.* **80**, 562-575.
96. Varma, S. and Cohen, H. J. (1997). Co-transactivation of the 3' erythropoietin hypoxia inducible enhancer by the HIF-1 protein. *Blood Cells Mol Dis.* **23**, 169-176.
97. Liu, L. X., Lu, H., Luo, Y., Date, T., Belanger, A. J., Vincent, K. A., Akita, G. Y., Goldberg, M., Cheng, S. H., Gregory, R. J., and Jiang, C. (2002). Stabilization of vascular endothelial growth factor mRNA by hypoxia- inducible factor 1. *Biochem.Biophys.Res Commun.* **291**, 908-914.
98. Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Kawamura, K., Hosokawa, M., and Asaka, M. (2001). Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. *Cancer Res* **61**, 6548-6554.

99. Wang, G. L., Jiang, B., Rue, E. A., and Semenza, G. L. (1995). Hypoxia-Inducible Factor 1 is a Basic-Helix-Loop-Helix-PAS Heterodimer Regulated by Cellular O₂ Tension. *PNAS* **92**, 5510-5514.
100. Jiang, B. H., Rue, E., Wang, G. L., Roe, R., and Semenza, G. L. (1996). Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. *J Biol Chem.* **271**, 17771-17778.
101. Yang, J., Zhang, L., Erbel, P. J., Gardner, K. H., Ding, K., Garcia, J. A., and Bruick, R. K. (2005). Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor. *J Biol Chem.* **280**, 36047-36054.
102. Chapman-Smith, A., Lutwyche, J. K., and Whitelaw, M. L. (2004). Contribution of the Per/Arnt/Sim (PAS) Domains to DNA Binding by the Basic Helix-Loop-Helix PAS Transcriptional Regulators. *J.Biol.Chem.* **279**, 5353-5362.
103. Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M., and Ratcliffe, P. J. (1997). Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. *J Biol Chem.* **272**, 11205-11214.
104. Luo, J. C. and Shibuya, M. (2001). A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1alpha, 2alpha and 3alpha). *Oncogene* **20**, 1435-1444.
105. Hankinson, O. (1995). The aryl hydrocarbon receptor complex. *Annu.Rev Pharmacol Toxicol.* **35**, 307-340.
106. Woods, S. L. and Whitelaw, M. L. (2002). Differential Activities of Murine Single Minded 1 (SIM1) and SIM2 on a Hypoxic Response Element. CROSS-TALK BETWEEN BASIC HELIX-LOOP-HELIX/Per-Arnt-Sim HOMOLOGY TRANSCRIPTION FACTORS. *J.Biol.Chem.* **277**, 10236-10243.
107. Lee, K. H., Park, J. W., and Chun, Y. S. (2004). Non-hypoxic transcriptional activation of the aryl hydrocarbon receptor nuclear translocator in concert with a novel hypoxia-inducible factor-1alpha isoform. *Nucl.Acids.Res.* **32**, 5499-5511.
108. Maltepe, E., Keith, B., Arsham, A. M., Brorson, J. R., and Simon, M. C. (2000). The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. *Biochem.Biophys.Res Commun.* **273**, 231-238.
109. Liu, C., Goshu, E., Wells, A., and Fan, C. M. (2003). Identification of the downstream targets of SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation. *J Biol Chem.* **278**, 44857-44867.
110. Takahata, S., Sogawa, K., Kobayashi, A., Ema, M., Mimura, J., Ozaki, N., and Fujii-Kuriyama, Y. (1998). Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-1a, HLF, and clock. *Biochem Biophys.Res Commun.* **248**, 789-794.
111. Pollenz, R. S., Davarinos, N. A., and Shearer, T. P. (1999). Analysis of aryl hydrocarbon receptor-mediated signaling during physiological hypoxia reveals lack of competition for the aryl hydrocarbon nuclear translocator transcription factor. *Mol Pharmacol* **56**, 1127-1137.
112. Minet, E., Ernest, I., Michel, G., Roland, I., Remacle, J., Raes, M., and Michiels, C. (1999). HIF1A gene transcription is dependent on a core promoter sequence encompassing activating and inhibiting sequences located upstream from the transcription initiation site and cis elements located within the 5'UTR. *Biochem Biophys.Res Commun.* **261**, 534-540.
113. Salceda, S. and Caro, J. (1997). Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. *J Biol Chem.* **272**, 22642-22647.
114. Ohh, M. and Kaelin, W. G., Jr. (1999). The von Hippel-Lindau tumour suppressor protein: new perspectives. *Mol Med.Today* **5**, 257-263.

115. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. (2000). Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. *EMBO J.* **19**, 4298-4309.
116. Groulx, I. and Lee, S. (2002). Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor Suppressor Protein. *Mol. Cell. Biol.* **22**, 5319.
117. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., and Kaelin, W. G., Jr. (2001). HIFalpha Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O₂ Sensing. *Science* **292**, 464-468.
118. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. v., Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. (2001). Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O₂-Regulated Prolyl Hydroxylation. *Science* **292**, 468-472.
119. Hon, W. C., Wilson, M. I., Harlos, K., Claridge, T. D., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., and Jones, E. Y. (2002). Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. *Nature* **417**, 975-978.
120. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. (2001). Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. *EMBO J.* **20**, 5197-5206.
121. Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N., Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W., Schofield, C. J., and Ratcliffe, P. J. (2001). *C. elegans* EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell* **107**, 43-54.
122. McNeill, L. A., Hewitson, K. S., Gleadle, J. M., Horsfall, L. E., Oldham, N. J., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., and Schofield, C. J. (2002). The use of dioxygen by HIF prolyl hydroxylase (PHD1). *Bioorg. Med. Chem. Lett.* **12**, 1547-1550.
123. Huang, J., Zhao, Q., Mooney, S. M., and Lee, F. S. (2002). Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. *J. Biol. Chem.* **277**, 39792-39800.
124. Kageyama, Y., Koshiji, M., To, K. K. W., Tian, Y. M., Ratcliffe, P. J., and Huang, L. E. (2004). Leu-574 of human HIF-1alpha; is a molecular determinant of prolyl hydroxylation. *FASEB J.* **03-1233**fe.
125. Esteban, M. A. and Maxwell, P. H. (2005). HIF, a missing link between metabolism and cancer. *Nat Med* **11**, 1047-1048.
126. Knowles, H. J., Raval, R. R., Harris, A. L., and Ratcliffe, P. J. (2003). Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. *Cancer Res* **63**, 1764-1768.
127. Clarke, H. and Pallister, C. J. (2005). The impact of anaemia on outcome in cancer. *Clin Lab Haematol* **27**, 1-13.
128. Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K. I., and Myllyharju, J. (2003). Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor. *J. Biol. Chem.* **278**, 30772-30780.
129. Erez, N., Stambolsky, P., Shats, I., Milyavsky, M., Kachko, T., and Rotter, V. (2004). Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter. *FEBS Letters* **567**, 311-315.

130. Marxsen, J. H., Stengel, P., Doege, K., Heikkinen, P., Jokilehto, T., Wagner, T., Jelkmann, W., Jaakkola, P., and Metzén, E. (2004). Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF- α -prolyl-4-hydroxylases. *Biochem J* **381**, 761-767.
131. Aprelikova, O., Chandramouli, G. V., Wood, M., Vasselli, J. R., Riss, J., Maranchie, J. K., Linehan, W. M., and Barrett, J. C. (2004). Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. *J Cell Biochem* **92**, 491-501.
132. Berra, E., Richard, D. E., Gothie, E., and Pouyssegur, J. (2001). HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1[α] degradation. *FEBS Letters* **491**, 85-90.
133. Nakayama, K., Frew, I. J., Hagensen, M., Skals, M., Habelhah, H., Bhoumik, A., Kadoya, T., Erdjument-Bromage, H., Tempst, P., Frappell, P. B., Bowtell, D. D., and Ronai, Z. (2004). Siah2 regulates stability of prolyl-hydroxylases, controls HIF1 α abundance, and modulates physiological responses to hypoxia. *Cell* **117**, 941-952.
134. Appelhoff, R. J., Tian, Y. M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., and Gleadle, J. M. (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. *J Biol Chem*. **279**, 38458-38465.
135. Tuckerman, J. R., Zhao, Y., Hewitson, K. S., Tian, Y. M., Pugh, C. W., Ratcliffe, P. J., and Mole, D. R. (2004). Determination and comparison of specific activity of the HIF-prolyl hydroxylases. *FEBS Letters* **576**, 145-150.
136. Chan, D. A., Sutphin, P. D., Yen, S. E., and Giaccia, A. J. (2005). Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 α . *Mol Cell Biol* **25**, 6415-6426.
137. Metzén, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang, W. Q., Wotzlaw, C., Hellwig-Burgel, T., Jelkmann, W., Acker, H., and Fandrey, J. (2003). Intracellular localisation of human HIF-1{ α } hydroxylases: implications for oxygen sensing. *J Cell Sci* **116**, 1319.
138. Baek, J. H., Mahon, P. C., Oh, J., Kelly, B., Krishnamachary, B., Pearson, M., Chan, D. A., Giaccia, A. J., and Semenza, G. L. (2005). OS-9 interacts with hypoxia-inducible factor 1 α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1 α . *Mol Cell* **17**, 503-512.
139. Berra, E., Benizri, E., Ginouves, A., Volmat, V., Roux, D., and Pouyssegur, J. (2003). HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1{ α } in normoxia. *EMBO J*. **22**, 4082-4090.
140. Madden, S. L., Galella, E. A., Riley, D., Bertelsen, A. H., and Beaudry, G. A. (1996). Induction of cell growth regulatory genes by p53. *Cancer Res* **56**, 5384-5390.
141. Seth, P., Krop, I., Porter, D., and Polyak, K. (2002). Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). *Oncogene* **21**, 836-843.
142. Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., Yoo, M. A., Song, E. J., Lee, K. J., and Kim, K. W. (2002). Regulation and destabilization of HIF-1 α by ARD1-mediated acetylation. *Cell* **111**, 709-720.
143. Bilton, R., Mazure, N., Trottier, E., Hattab, M., Dery, M. A., Richard, D. E., Pouyssegur, J., and Brahimi-Horn, M. C. (2005). Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1 α and is not induced by hypoxia or HIF. *J Biol Chem*. **280**, 31132-31140.
144. Arnesen, T., Kong, X., Evjenth, R., Gromyko, D., Varhaug, J. E., Lin, Z., Sang, N., Caro, J., and Lillehaug, J. R. (2005). Interaction between HIF-1 α (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 α . *FEBS Lett*. **579**, 6428-6432.

145. Fisher, T. S., Etages, S. D., Hayes, L., Crimin, K., and Li, B. (2005). Analysis of ARD1 function in hypoxia response using retroviral RNA interference. *J Biol Chem.* **280**, 17749-17757.
146. Li, L. and Deng, X. W. (2003). The COP9 signalosome: an alternative lid for the 26S proteasome? *Trends Cell Biol* **13**, 507-509.
147. Bemis, L., Chan, D. A., Finkielstein, C. V., Qi, L., Sutphin, P. D., Chen, X., Stenmark, K., Giaccia, A. J., and Zundel, W. (2004). Distinct aerobic and hypoxic mechanisms of HIF- α regulation by CSN5. *Genes Dev.* **18**, 739-744.
148. Li, Z., Wang, D., Messing, E. M., and Wu, G. (2005). VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1 α . *EMBO Rep.* **6**, 373-378.
149. Mekhail, K., Gunaratnam, L., Bonicalzi, M. E., and Lee, S. (2004). HIF activation by pH-dependent nucleolar sequestration of VHL. *Nat Cell Biol* **6**, 642-647.
150. Karhausen, J., Kong, T., Narravula, S., and Colgan, S. P. (2005). Induction of the von Hippel-Lindau tumor suppressor gene by late hypoxia limits HIF-1 expression. *J Cell Biochem* **95**, 1264-1275.
151. Bae, S. H., Jeong, J. W., Park, J. A., Kim, S. H., Bae, M. K., Choi, S. J., and Kim, K. W. (2004). Sumoylation increases HIF-1 α stability and its transcriptional activity. *Biochem Biophys. Res Commun.* **324**, 394-400.
152. Seeler, J. S. and Dejean, A. (2003). Nuclear and unclear functions of SUMO. *Nat Rev Mol Cell Biol* **4**, 690-699.
153. Shao, R., Zhang, F. P., Tian, F., Anders, F. P., Wang, X., Sjoland, H., and Billig, H. (2004). Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1 α in adult mouse brain and heart in vivo. *FEBS Lett.* **569**, 293-300.
154. Tojo, M., Matsuzaki, K., Minami, T., Honda, Y., Yasuda, H., Chiba, T., Saya, H., Fujii-Kuriyama, Y., and Nakao, M. (2002). The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system. *J Biol Chem.* **277**, 46576-46585.
155. Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Lowe, S. W., Kastan, M., and Giaccia, A. (2001). Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. *Mol Cell Biol* **21**, 1297-1310.
156. Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J., and Simon, M. C. (2004). p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. *Oncogene* **23**, 4975-4983.
157. Kaluzova, M., Kaluz, S., Lerman, M. I., and Stanbridge, E. J. (2004). DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1 α in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. *Mol Cell Biol* **24**, 5757-5766.
158. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. (2000). Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 α . *Genes Dev.* **14**, 34-44.
159. Suzuki, H., Tomida, A., and Tsuruo, T. (2001). Dephosphorylated hypoxia-inducible factor 1 α as a mediator of p53-dependent apoptosis during hypoxia. *Oncogene* **20**, 5779-5788.
160. Bae, M. K., Ahn, M. Y., Jeong, J. W., Bae, M. H., Lee, Y. M., Bae, S. K., Park, J. W., Kim, K. R., and Kim, K. W. (2001). Jab1 Interacts Directly with HIF-1 α and Regulates Its Stability. *J. Biol. Chem.* **277**, 9-12.
161. Hansson, L. O., Friedler, A., Freund, S., Rudiger, S., and Fersht, A. R. (2002). Two sequence motifs from HIF-1 α bind to the DNA-binding site of p53. *PNAS* **99**, 10305-10309.
162. Chen, D., Li, M., Luo, J., and Gu, W. (2003). Direct Interactions between HIF-1 α and Mdm2 Modulate p53 Function. *J. Biol. Chem.* **278**, 13595.

163. Schmid, T., Zhou, J., Kohl, R., and Brune, B. (2004). p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). *Biochem J* **380**, 289-295.
164. Nieminen, A. L., Qanungo, S., Schneider, E. A., Jiang, B. H., and Agani, F. H. (2005). Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. *J Cell Physiol* **204**, 364-369.
165. Zhang, L. and Hill, R. P. (2004). Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. *Cancer Res* **64**, 4180-4189.
166. Yoo, Y. G., Yeo, M. G., Kim, D. K., Park, H., and Lee, M. O. (2004). Novel Function of Orphan Nuclear Receptor Nur77 in Stabilizing Hypoxia-inducible Factor-1{alpha}. *J.Biol.Chem.* **279**, 53365-53373.
167. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. (1998). Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. *Nature* **392**, 405-408.
168. Wenger, R. H., Camenisch, G., Desbaillets, I., Chilov, D., and Gassmann, M. (1998). Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. *Cancer Res* **58**, 5678-5680.
169. Jiang, B. H., Semenza, G. L., Bauer, C., and Marti, H. H. (1996). Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. *Am J Physiol* **271**, C1172-C1180.
170. Schmid, T., Zhou, J., and Brune, B. (2004). HIF-1 and p53: communication of transcription factors under hypoxia. *J Cell Mol Med* **8**, 423-431.
171. Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle, J., and Michiels, C. (1999). Hypoxia-induced activation of HIF-1: role of HIF-1[alpha]-Hsp90 interaction. *FEBS Letters* **460**, 251-256.
172. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. (2002). Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha -degradative Pathway. *J.Biol.Chem.* **277**, 29936-29944.
173. Hur, E., Kim, H. H., Choi, S. M., Kim, J. H., Yim, S., Kwon, H. J., Choi, Y., Kim, D. K., Lee, M. O., and Park, H. (2002). Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. *Mol Pharmacol* **62**, 975-982.
174. Agani, F. H., Puchowicz, M., Chavez, J. C., Pichiule, P., and LaManna, J. (2002). Role of nitric oxide in the regulation of HIF-1alpha expression during hypoxia. *Am.J.Physiol Cell Physiol* **283**, C178-C186.
175. Hagen, T., Taylor, C. T., Lam, F., and Moncada, S. (2003). Redistribution of Intracellular Oxygen in Hypoxia by Nitric Oxide: Effect on HIF1{alpha}. *Science* **302**, 1975-1978.
176. Palmer, L. A., Semenza, G. L., Stoler, M. H., and Johns, R. A. (1998). Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. *Am J Physiol* **274**, L212-L219.
177. Mateo, J., Garcia-Lecea, M., Cadenas, S., Hernandez, C., and Moncada, S. (2003). Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. *Biochem J* **376**, 537-544.
178. Denko, N., Wernke-Dollries, K., Johnson, A. B., Hammond, E., Chiang, C. M., and Barton, M. C. (2003). Hypoxia Actively Represses Transcription by Inducing Negative Cofactor 2 (Dr1/DrAP1) and Blocking Preinitiation Complex Assembly. *J.Biol.Chem.* **278**, 5744.
179. Wouters, B. G., van den, B. T., Magagnin, M. G., Koritzinsky, M., Fels, D., and Koumenis, C. (2005). Control of the hypoxic response through regulation of mRNA translation. *Semin Cell Dev Biol* **16**, 487-501.

180. Lang, K. J. D., Kappel, A., and Goodall, G. J. (2002). Hypoxia-inducible Factor-1alpha mRNA Contains an Internal Ribosome Entry Site That Allows Efficient Translation during Normoxia and Hypoxia. *Mol.Biol.Cell* **13**, 1792.
181. Rossignol, F., Vache, C., and Clottes, E. (2002). Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. *Gene* **299**, 135-140.
182. Arany, Z., Huang, L. á., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M., Bunn, H. á., and Livingston, D. (1996). An essential role for p300/CBP in the cellular response to hypoxia. *PNAS* **93**, 12969-12973.
183. Carrero, P., Okamoto, K., Coumailleau, P., O'Brien, S., Tanaka, H., and Poellinger, L. (2000). Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. *Mol Cell Biol.* **20**, 402-415.
184. Lando, D., Pongratz, I., Poellinger, L., and Whitelaw, M. L. (2000). A Redox Mechanism Controls Differential DNA Binding Activities of Hypoxia-inducible Factor (HIF) 1alpha and the HIF-like Factor. *J.Biol.Chem.* **275**, 4618-4627.
185. McNeill, L. A., Hewitson, K. S., Claridge, T. D., Seibel, J. F., Horsfall, L. E., and Schofield, C. J. (2002). Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. *Biochem J* **367**, 571-575.
186. Freedman, S. J., Sun, Z. Y., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G., and Eck, M. J. (2002). Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1alpha. *PNAS* **99**, 5367-5372.
187. Linke, S., Stojkoski, C., Kewley, R. J., Booker, G. W., Whitelaw, M. L., and Peet, D. J. (2004). Substrate Requirements of the Oxygen-sensing Asparaginyl Hydroxylase Factor-inhibiting Hypoxia-inducible Factor. *J.Biol.Chem.* **279**, 14391-14397.
188. Lancaster, D. E., McNeill, L. A., McDonough, M. A., Aplin, R. T., Hewitson, K. S., Pugh, C. W., Ratcliffe, P. J., and Schofield, C. J. (2004). Disruption of dimerization and substrate phosphorylation inhibit factor inhibiting hypoxia-inducible factor (FIH) activity. *Biochem J* **383**, 429-437.
189. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., and Whitelaw, M. L. (2002). Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch. *Science* **295**, 858-861.
190. Koivunen, P., Hirsila, M., Gunzler, V., Kivirikko, K. I., and Myllyharju, J. (2004). Catalytic Properties of the Asparaginyl Hydroxylase (FIH) in the Oxygen Sensing Pathway Are Distinct from Those of Its Prolyl 4-Hydroxylases. *J.Biol.Chem.* **279**, 9899-9904.
191. Koshiji, M., Kageyama, Y., Pete, E. A., Horikawa, I., Barrett, J. C., and Huang, L. E. (2004). HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. *EMBO J* **23**, 1949-1956.
192. Lee, C., Kim, S. J., Jeong, D. G., Lee, S. M., and Ryu, S. E. (2003). Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel-Lindau. *J.Biol.Chem.* **278**, 7558.
193. Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., and Caro, J. (2002). Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. *Mol Cell Biol* **22**, 2984-2992.
194. Mahon, P. C., Hirota, K., and Semenza, G. L. (2001). FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. *Genes Dev.* **15**, 2675-2686.
195. Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., and Wu, G. (2003). The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1{alpha} transcriptional activity. *EMBO J.* **22**, 1857.

196. Kato, H., Tamamizu-Kato, S., and Shibasaki, F. (2004). Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. *J Biol Chem.* **279**, 41966-41974.
197. Minet, E., Michel, G., Mottet, D., Raes, M., and Michiels, C. (2001). Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. *Free Radic.Biol.Med.* **31**, 847-855.
198. Sodhi, A., Montaner, S., Miyazaki, H., and Gutkind, J. S. (2001). MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. *Biochem.Biophys.Res Commun.* **287**, 292-300.
199. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia- inducible factor 1. *Cell Growth Differ.* **12**, 363-369.
200. Alvarez-Tejado, M., Alfranca, A., Aragonés, J., Vara, A., Landazuri, M. O., and del Peso, L. (2002). Lack of Evidence for the Involvement of the Phosphoinositide 3-Kinase/Akt Pathway in the Activation of Hypoxia-inducible Factors by Low Oxygen Tension. *J.Biol.Chem.* **277**, 13508-13517.
201. Arsham, A. M., Howell, J. J., and Simon, M. C. (2003). A Novel Hypoxia-inducible Factor-independent Hypoxic Response Regulating Mammalian Target of Rapamycin and Its Targets. *J.Biol.Chem.* **278**, 29655-29660.
202. Tang, T. T.-L. and Lasky, L. A. (2003). The Forkhead Transcription Factor FOXO4 Induces the Down-regulation of Hypoxia-inducible Factor 1{alpha} by a von Hippel-Lindau Protein-independent Mechanism. *J.Biol.Chem.* **278**, 30125-30135.
203. Zhou, J., Schmid, T., Frank, R., and Brune, B. (2004). PI3K/Akt Is Required for Heat Shock Proteins to Protect Hypoxia-inducible Factor 1{alpha} from pVHL-independent Degradation. *J.Biol.Chem.* **279**, 13506-13513.
204. Beitner-Johnson, D., Rust, R. T., Hsieh, T. C., and Millhorn, D. E. (2001). Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells. *Cell Signal.* **13**, 23-27.
205. Mottet, D., Dumont, V., Deccache, Y., Demazy, C., Ninane, N., Raes, M., and Michiels, C. (2003). Regulation of Hypoxia-inducible Factor-1{alpha} Protein Level during Hypoxic Conditions by the Phosphatidylinositol 3-Kinase/Akt/Glycogen Synthase Kinase 3{beta} Pathway in HepG2 Cells. *J.Biol.Chem.* **278**, 31277-31285.
206. Hur, E., Chang, K. Y., Lee, E., Lee, S. K., and Park, H. (2001). Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. *Mol Pharmacol* **59**, 1216-1224.
207. Berra, E., Milanini, J., Richard, D. E., Le Gall, M., Vinals, F., Gothie, E., Roux, D., Pages, G., and Pouyssegur, J. (2000). Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. *Biochem.Pharmacol* **60**, 1171-1178.
208. Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., and Caro, J. (2003). MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300. *J.Biol.Chem.* **278**, 14013.
209. Liu, C., Shi, Y., Han, Z., Pan, Y., Liu, N., Han, S., Chen, Y., Lan, M., Qiao, T., and Fan, D. (2003). Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and increases expression of EPO. *Biochemical and Biophysical Research Communications* **312**, 780-786.
210. Conrad, P. W., Rust, R. T., Han, J., Millhorn, D. E., and Beitner-Johnson, D. (1999). Selective activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in PC12 cells. *J Biol Chem.* **274**, 23570-23576.

211. Le, Y. J. and Corry, P. M. (1999). Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathway. *Mol Cell Biochem* **202**, 1-8.
212. Lee, M., Hwang, J. T., Lee, H. J., Jung, S. N., Kang, I., Chi, S. G., Kim, S. S., and Ha, J. (2003). AMP-activated Protein Kinase Activity Is Critical for Hypoxia-inducible Factor-1 Transcriptional Activity and Its Target Gene Expression under Hypoxic Conditions in DU145 Cells. *J.Biol.Chem.* **278**, 39653-39661.
213. Mottet, D., Ruys, S. P., Demazy, C., Raes, M., and Michiels, C. (2005). Role for casein kinase 2 in the regulation of HIF-1 activity. *Int J Cancer* **117**, 764-774.
214. Colavitti, R., Pani, G., Bedogni, B., Anzevino, R., Borrello, S., Waltenberger, J., and Galeotti, T. (2002). Reactive Oxygen Species as Downstream Mediators of Angiogenic Signaling by Vascular Endothelial Growth Factor Receptor-2/KDR. *J.Biol.Chem.* **277**, 3101-3108.
215. Zulueta, J. J., Yu, F. S., Hertig, I. A., Thannickal, V. J., and Hassoun, P. M. (1995). Release of hydrogen peroxide in response to hypoxia-reoxygenation: role of an NAD(P)H oxidase-like enzyme in endothelial cell plasma membrane. *Am J Respir.Cell Mol Biol* **12**, 41-49.
216. Osada, M., Imaoka, S., Sugimoto, T., Hiroi, T., and Funae, Y. (2002). NADPH-Cytochrome P-450 Reductase in the Plasma Membrane Modulates the Activation of Hypoxia-inducible Factor 1. *J.Biol.Chem.* **277**, 23367-23373.
217. Bell, E. L., Emerling, B. M., and Chandel, N. S. (2005). Mitochondrial regulation of oxygen sensing. *Mitochondrion*. **5**, 322-332.
218. Mansfield, K. D., Guzy, R. D., Pan, Y., Young, R. M., Cash, T. P., Schumacker, P. T., and Simon, M. C. (2005). Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. *Cell Metab* **1**, 393-399.
219. Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., and Schumacker, P. T. (2000). Reactive Oxygen Species Generated at Mitochondrial Complex III Stabilize Hypoxia-inducible Factor-1alpha during Hypoxia. A MECHANISM OF O2 SENSING. *J.Biol.Chem.* **275**, 25130-25138.
220. Sanjuan-Pla, A., Cervera, A. M., Apostolova, N., Garcia-Bou, R., Victor, V. M., Murphy, M. P., and McCreath, K. J. (2005). A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha. *FEBS Lett.* **579**, 2669-2674.
221. Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., and Schumacker, P. T. (1998). Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. *Proc Natl Acad Sci U S A* **95**, 11715-11720.
222. Vaux, E. C., Metzen, E., Yeates, K. M., and Ratcliffe, P. J. (2001). Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. *Blood* **98**, 296-302.
223. Emerling, B. M., Plataniias, L. C., Black, E., Nebreda, A. R., Davis, R. J., and Chandel, N. S. (2005). Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. *Mol Cell Biol* **25**, 4853-4862.
224. Schroedl, C., McClintock, D. S., Budinger, G. R., and Chandel, N. S. (2002). Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. *Am.J Physiol Lung Cell Mol Physiol* **283**, L922-L931.
225. To, K. K. and Huang, L. E. (2005). Suppression of HIF-1alpha transcriptional activity by the HIF prolyl hydroxylase EGLN1. *J Biol Chem.*
226. Ozer, A., Wu, L. C., and Bruick, R. K. (2005). The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). *Proc Natl Acad Sci U S A* **102**, 7481-7486.

227. Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A., and Ohh, M. (2005). Human HIF-3 α 4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. *FASEB J* **19**, 1396-1406.
228. Bhattacharya, S., Michels, C. L., Leung, M. K., Arany, Z. P., Kung, A. L., and Livingston, D. M. (1999). Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. *Genes Dev.* **13**, 64-75.
229. Fox, S. B., Braganca, J., Turley, H., Campo, L., Han, C., Gatter, K. C., Bhattacharya, S., and Harris, A. L. (2004). CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1 α . *Cancer Res* **64**, 6075-6081.
230. Tacchini, L., Dansi, P., Matteucci, E., and Desiderio, M. A. (2001). Hepatocyte growth factor signalling stimulates hypoxia inducible factor- 1 (HIF-1) activity in HepG2 hepatoma cells. *Carcinogenesis* **22**, 1363-1371.
231. Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., and Semenza, G. L. (2002). Insulin-like growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. *J Biol.Chem.* **277**, 38205-38211.
232. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. (2000). Modulation of Hypoxia-inducible Factor 1 α Expression by the Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics. *Cancer Res* **60**, 1541-1545.
233. Shi, Y. H., Wang, Y. X., You, J. F., Heng, W. J., Zhong, H. H., and Fang, W. G. (2004). [Activation of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways.]. *Zhonghua Yi.Xue.Za Zhi.* **84**, 1899-1903.
234. Stiehl, D. P., Jelkmann, W., Wenger, R. H., and Hellwig-Burgel, T. (2002). Normoxic induction of the hypoxia-inducible factor 1 α by insulin and interleukin-1 β involves the phosphatidylinositol 3-kinase pathway. *FEBS Letters* **512**, 157-162.
235. Moeller, L. C., Dumitrescu, A. M., and Refetoff, S. (2005). Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1 α and glycolytic genes. *Mol Endocrinol* **19**, 2955-2963.
236. Mabeesh, N. J., Willard, M. T., Frederickson, C. E., Zhong, H., and Simons, J. W. (2003). Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. *Clin Cancer Res* **9**, 2416-2425.
237. Zhou, J., Schmid, T., and Brune, B. (2003). Tumor Necrosis Factor- α Causes Accumulation of a Ubiquitinated Form of Hypoxia Inducible Factor-1 α through a Nuclear Factor- κ B-Dependent Pathway. *Mol.Biol.Cell* **14**, 2216-2225.
238. Spinella, F., Rosano, L., Di Castro, V., Natali, P. G., and Bagnato, A. (2002). Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1 α in Ovarian Carcinoma Cells. *J.Biol.Chem.* **277**, 27850-27855.
239. Chun, Y. S., Choi, E., Kim, G. T., Lee, M. J., Lee, M. J., Lee, S. E., Kim, M. S., and Park, J. W. (2000). Zinc induces the accumulation of hypoxia-inducible factor (HIF)-1 α , but inhibits the nuclear translocation of HIF-1 β , causing HIF-1 inactivation. *Biochem.Biophys.Res Commun.* **268**, 652-656.

240. Lee, S. G., Lee, H., and Rho, H. M. (2001). Transcriptional repression of the human p53 gene by cobalt chloride mimicking hypoxia. *FEBS Lett.* **507**, 259-263.
241. Gao, N., Ding, M., Zheng, J. Z., Zhang, Z., Leonard, S. S., Liu, K. J., Shi, X., and Jiang, B. H. (2002). Vanadate-induced Expression of Hypoxia-inducible Factor 1alpha and Vascular Endothelial Growth Factor through Phosphatidylinositol 3-Kinase/Akt Pathway and Reactive Oxygen Species. *J.Biol.Chem.* **277**, 31963-31971.
242. Gao, N., Jiang, B. H., Leonard, S. S., Corum, L., Zhang, Z., Roberts, J. R., Antonini, J., Zheng, J. Z., Flynn, D. C., Castranova, V., and Shi, X. (2002). p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. *J.Biol.Chem.* **277**, 45041-45048.
243. Sandau, K. B., Zhou, J., Kietzmann, T., and Brune, B. (2001). Regulation of the Hypoxia-inducible Factor 1alpha by the Inflammatory Mediators Nitric Oxide and Tumor Necrosis Factor-alpha in Contrast to Desferroxamine and Phenylarsine Oxide. *J.Biol.Chem.* **276**, 39805-39811.
244. Chong, T. W., Horwitz, L. D., Moore, J. W., Sowter, H. M., and Harris, A. L. (2002). A mycobacterial iron chelator, desferri-exochelin, induces hypoxia- inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. *Cancer Res* **62**, 6924-6927.
245. Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. Activation of the HIF pathway in cancer. *Current Opinion in Genetics and Development* **11**, 293-299. 2001. Ref Type: Generic
246. Wakisaka, N., Kondo, S., Yoshizaki, T., Murono, S., Furukawa, M., and Pagano, J. S. (2004). Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. *Mol Cell Biol* **24**, 5223-5234.
247. Sanchez-Elsner, T., Botella, L. M., Velasco, B., Corbi, A., Attisano, L., and Bernabeu, C. (2001). Synergistic Cooperation between Hypoxia and Transforming Growth Factor-beta Pathways on Human Vascular Endothelial Growth Factor Gene Expression. *J.Biol.Chem.* **276**, 38527-38535.
248. Zhang, S. X. L., Gozal, D., Sachleben, J., Rane, M., Klein, J. B., and Gozal, E. (2003). Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF- β receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells. *FASEB J.* **17**, 1111-1119.
249. Tacchini, L., Matteucci, E., De Ponti, C., and Desiderio, M. A. (2003). Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. *Exp Cell Res* **290**, 391-401.
250. Zhu, G., Saed, G. M., Deppe, G., Diamond, M. P., and Munkarah, A. R. (2004). Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. *Gynecol.Oncol* **94**, 422-426.
251. Lison, D., De Boeck, M., Verougstraete, V., and Kirsch-Volders, M. (2001). Update on the genotoxicity and carcinogenicity of cobalt compounds. *Occup. Environ. Med* **58**, 619-625.
252. Williams, D. R. (1972). Metals, ligands, and cancer. *Chem.Rev* **72**, 203-213.
253. Salnikow, K., Donald, S. P., Bruick, R. K., Zhitkovich, A., Phang, J. M., and Kasprzak, K. S. (2004). Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. *J Biol Chem.* **279**, 40337-40344.
254. Hirsila, M., Koivunen, P., Xu, L., Seeley, T., Kivirikko, K. I., and Myllyharju, J. (2005). Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. *FASEB J* **19**, 1308-1310.

255. Yuan, Y., Beitner-Johnson, D., and Millhorn, D. E. (2001). Hypoxia-inducible factor 2alpha binds to cobalt in vitro. *Biochem.Biophys.Res Commun.* **288**, 849-854.
256. Yuan, Y., Hilliard, G., Ferguson, T., and Millhorn, D. E. (2003). Cobalt Inhibits the Interaction between Hypoxia-inducible Factor-alpha and von Hippel-Lindau Protein by Direct Binding to Hypoxia-inducible Factor-alpha. *J.Biol.Chem.* **278**, 15911.
257. Kanaya, K., Tsai, A. L., and Kamitani, T. (2002). Cobalt- and nickel-binding property of cullin-2. *Biochem.Biophys.Res Commun.* **290**, 294-299.
258. Chachami, G., Simos, G., Hatziefthimiou, A., Bonanou, S., Molyvdas, P. A., and Paraskeva, E. (2004). Cobalt induces hypoxia-inducible factor-1alpha expression in airway smooth muscle cells by a reactive oxygen species- and PI3K-dependent mechanism. *Am J Respir.Cell Mol Biol* **31**, 544-551.
259. Peters, K., Schmidt, H., Unger, R. E., Kamp, G., Prols, F., Berger, B. J., and Kirkpatrick, C. J. (2005). Paradoxical effects of hypoxia-mimicking divalent cobalt ions in human endothelial cells in vitro. *Mol Cell Biochem* **270**, 157-166.
260. Sandau, K. B., Fandrey, J., and Brune, B. (2001). Accumulation of HIF-1alpha under the influence of nitric oxide. *Blood* **97**, 1009-1015.
261. Kasuno, K., Takabuchi, S., Fukuda, K., Kizaka-Kondoh, S., Yodoi, J., Adachi, T., Semenza, G. L., and Hirota, K. (2004). Nitric Oxide Induces Hypoxia-inducible Factor 1 Activation That Is Dependent on MAPK and Phosphatidylinositol 3-Kinase Signaling. *J.Biol.Chem.* **279**, 2550-2558.
262. Yasinska, I. M. and Sumbayev, V. V. (2003). S-nitrosation of Cys-800 of HIF-1[alpha] protein activates its interaction with p300 and stimulates its transcriptional activity. *FEBS Letters* **549**, 105-109.
263. Zhang, Z., Ren, J., Harlos, K., McKinnon, C. H., Clifton, I. J., and Schofield, C. J. (2002). Crystal structure of a clavamate synthase-Fe(II)-2-oxoglutarate-substrate-NO complex: evidence for metal centered rearrangements. *FEBS Lett.* **517**, 7-12.
264. Zhong, H., Mabeesh, N., Willard, M., and Simons, J. (2002). Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. *Cancer Lett.* **181**, 233-238.
265. Anastasiadis, A. G., Ghafar, M. A., Salomon, L., Vacherot, F., Bénédict, P., Chen, M. W., Shabsigh, A., Burchardt, M., Chopin, D. K., Shabsigh, R., and Buttyan, R. (2002). Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). *J Cancer Res Clin Oncol* **128**, 358-362.
266. Chau, C. H., Permenter, M. G., Steinberg, S. M., Retter, A. S., Dahut, W. L., Price, D. K., and Figg, W. D. (2005). Polymorphism in the Hypoxia-Inducible Factor 1alpha Gene May Confer Susceptibility to Androgen-Independent Prostate Cancer. *Cancer Biol Ther* **4**.
267. Tanimoto, K., Yoshiga, K., Eguchi, H., Kaneyasu, M., Ukon, K., Kumazaki, T., Oue, N., Yasui, W., Imai, K., Nakachi, K., Poellinger, L., and Nishiyama, M. (2003). Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. *Carcinogenesis* **24**, 1779-1783.
268. Ollerenshaw, M., Page, T., Hammonds, J., and Demaine, A. (2004). Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. *Cancer Genet Cytogenet.* **153**, 122-126.
269. Kuwai, T., Kitadai, Y., Tanaka, S., Kuroda, T., Ochiuni, T., Matsumura, S., Oue, N., Yasui, W., Kaneyasu, M., Tanimoto, K., Nishiyama, M., and Chayama, K. (2004). Single nucleotide

- polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. *Oncol Rep.* **12**, 1033-1037.
270. Fu, X. S., Choi, E., Bubley, G. J., and Balk, S. P. (2005). Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. *Prostate* **63**, 215-221.
271. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin, W. G., Jr. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel- Lindau protein. *Cancer Cell* **1**, 237-246.
272. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., and Klausner, R. D. (2002). The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. *Cancer Cell* **1**, 247-255.
273. Miller, F., Kentsis, A., Osman, R., and Pan, Z. Q. (2005). Inactivation of VHL by Tumorigenic Mutations That Disrupt Dynamic Coupling of the pVHL{middle dot}Hypoxia-inducible Transcription Factor-1{alpha} Complex. *J.Biol.Chem.* **280**, 7985-7996.
274. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliareisis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* **275**, 1943-1947.
275. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. (2000). Loss of PTEN facilitates HIF-1-mediated gene expression. *Genes Dev.* **14**, 391-396.
276. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991). p53 mutations in human cancers. *Science* **253**, 49-53.
277. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. *Nature* **387**, 299-303.
278. Fatyol, K. and Szalay, A. A. (2001). The p14ARF Tumor Suppressor Protein Facilitates Nucleolar Sequestration of Hypoxia-inducible Factor-1alpha (HIF-1alpha) and Inhibits HIF-1-mediated Transcription. *J.Biol.Chem.* **276**, 28421-28429.
279. Chan, D. A., Sutphin, P. D., Denko, N. C., and Giaccia, A. J. (2002). Role of prolyl hydroxylation in oncogenically stabilized hypoxia- inducible factor-1alpha. *J.Biol.Chem.* **277**, 40112-40117.
280. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. (1997). Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. *Blood* **90**, 3322-3331.
281. Racker, E., Resnick, R. J., and Feldman, R. (1985). Glycolysis and methylaminoisobutyrate uptake in rat-1 cells transfected with ras or myc oncogenes. *Proc Natl Acad Sci U S A* **82**, 3535-3538.
282. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. (1995). Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. *Cancer Res* **55**, 4575-4580.
283. Blancher, C., Moore, J. W., Robertson, N., and Harris, A. L. (2001). Effects of ras and von Hippel-Lindau (VHL) Gene Mutations on Hypoxia-inducible Factor (HIF)-1{alpha}, HIF-2{alpha}, and Vascular Endothelial Growth Factor Expression and Their Regulation by the Phosphatidylinositol 3'-Kinase/Akt Signaling Pathway. *Cancer Res* **61**, 7349-7355.
284. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. *Nature* **370**, 527-532.

285. Pouyssegur, J., Volmat, V., and Lenormand, P. (2002). Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. *Biochem Pharmacol* **64**, 755-763.
286. Karni, R., Dor, Y., Keshet, E., Meyuhas, O., and Levitzki, A. (2002). Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. *J Biol.Chem.* **277**, 42919-42925.
287. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., Keshet, E., and Keshet, E. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature* **394**, 485-490.
288. Uchida, T., Rossignol, F., Matthay, M. A., Mounier, R., Couette, S., Clottes, E., and Clerici, C. (2004). Prolonged Hypoxia Differentially Regulates Hypoxia-inducible Factor (HIF)-1{alpha} and HIF-2{alpha} Expression in Lung Epithelial Cells: IMPLICATION OF NATURAL ANTISENSE HIF-1{alpha}. *J.Biol.Chem.* **279**, 14871-14878.
289. Demidenko, Z. N., Rapisarda, A., Garayoa, M., Giannakakou, P., Melillo, G., and Blagosklonny, M. V. (2005). Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion. *Oncogene* **24**, 4829-4838.
290. Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., and Simon, M. C. (2003). Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. *Mol Cell Biol* **23**, 9361-9374.
291. Bracken, C. P., Whitelaw, M. L., and Peet, D. J. (2005). Activity of Hypoxia-inducible Factor 2{alpha} Is Regulated by Association with the NF- κ B Essential Modulator. *J.Biol.Chem.* **280**, 14240-14251.
292. Wiesener, M. S., Jurgensen, J. S., Rosenberger, C., Scholze, C. K., Horstrup, J. H., Warnecke, C., Mandriota, S., Bechmann, I., Frei, U. A., Pugh, C. W., Ratcliffe, P. J., Bachmann, S., Maxwell, P. H., and Eckardt, K. U. (2003). Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. *FASEB J* **17**, 271-273.
293. Wiesener, M. S., Turley, H., Allen, W. E., Willam, C., Eckardt, K. U., Talks, K. L., Wood, S. M., Gatter, K. C., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., and Maxwell, P. H. (1998). Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. *Blood* **92**, 2260-2268.
294. Holmquist, L., Jogi, A., and Pahlman, S. (2005). Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. *Int J Cancer* **116**, 218-225.
295. Wang, V., Davis, D. A., Haque, M., Huang, L. E., and Yarchoan, R. (2005). Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1{alpha} and Hypoxia-Inducible Factor-2{alpha} in HEK293T Cells. *Cancer Res* **65**, 3299-3306.
296. Brusselmans, K., Bono, F., Maxwell, P., Dor, Y., Dewerchin, M., Collen, D., Herbert, J. M., and Carmeliet, P. (2001). Hypoxia-inducible Factor-2alpha (HIF-2alpha) Is Involved in the Apoptotic Response to Hypoglycemia but Not to Hypoxia. *J.Biol.Chem.* **276**, 39192-39196.
297. Bertges, D. J., Berg, S., Fink, M. P., and Delude, R. L. (2002). Regulation of hypoxia-inducible factor 1 in enterocytic cells. *J.Surg.Res* **106**, 157-165.
298. Belanger, A. J., Lu, H., Date, T., Liu, L. X., Vincent, K. A., Akita, G. Y., Cheng, S. H., Gregory, R. J., and Jiang, C. (2002). Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha. *J.Mol Cell Cardiol.* **34** , 765-774.

299. Jung, F., Haendeler, J., Hoffmann, J., Reissner, A., Dernbach, E., Zeiher, A. M., and Dimmeler, S. (2002). Hypoxic Induction of the Hypoxia-Inducible Factor Is Mediated via the Adaptor Protein Shc in Endothelial Cells. *Circ Res* **91**, 38.
300. BelAiba, R. S., Djordjevic, T., Bonello, S., Flugel, D., Hess, J., Kietzmann, T., and Gorlach, A. (2004). Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells. *Biol Chem*. **385**, 249-257.
301. Wang, Y. Q., Luk, J. M., Ikeda, K., Man, K., Chu, A. C., Kaneda, K., and Tat Fan, S. (2004). Regulatory role of vHL/HIF-1[alpha] in hypoxia-induced VEGF production in hepatic stellate cells. *Biochemical and Biophysical Research Communications* **317**, 358-362.
302. Karhausen, J., Haase, V. H., and Colgan, S. P. (2005). Inflammatory hypoxia: role of hypoxia-inducible factor. *Cell Cycle* **4**, 256-258.
303. Scortegagna, M., Morris, M. A., Oktay, Y., Bennett, M., and Garcia, J. A. (2003). The HIF family member EPAS1/HIF-2{alpha} is required for normal hematopoiesis in mice. *Blood* **102**, 1634-1640.
304. Licht, A. H., Muller-Holtkamp, F., Flamme, I., and Breier, G. (2005). Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development. *Blood*.
305. Freiburg, P. B., Robert, B., St John, P. L., and Abrahamson, D. R. (2003). Podocyte expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. *J Am Soc.Nephrol.* **14**, 927-938.
306. Wagner, K. F., Hellberg, A. K., Balenger, S., Depping, R., Dodd, O., Johns, R. A., and Li, D. (2004). Hypoxia-induced mitogenic factor has antiapoptotic action and is upregulated in the developing lung: coexpression with hypoxia-inducible factor-2alpha. *Am J Respir.Cell Mol Biol* **31**, 276-282.
307. Scortegagna, M., Ding, K., Zhang, Q., Oktay, Y., Bennett, M. J., Bennett, M., Shelton, J. M., Richardson, J. A., Moe, O., and Garcia, J. A. (2005). HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. *Blood* **105**, 3133-3140.
308. Duan, L. J., Zhang-Benoit, Y., and Fong, G. H. (2005). Endothelium-intrinsic requirement for Hif-2alpha during vascular development. *Circulation* **111**, 2227-2232.
309. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. *Cancer Res* **59**, 5830-5835.
310. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G. (2001). Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. *Clin.Cancer Res* **7**, 1661-1668.
311. Theodoropoulos, V. E., Lazaris, A. C., Sofras, F., Gerzelis, I., Tsoukala, V., Ghikonti, I., Manikas, K., and Kastriotis, I. (2004). Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. *Eur Urol.* **46**, 200-208.
312. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch, J., Pak, B., Taghavi, P., and Semenza, G. L. (2003). Regulation of Colon Carcinoma Cell Invasion by Hypoxia-Inducible Factor 1. *Cancer Res* **63**, 1138.
313. Jogi, A., Vallon-Christersson, J., Holmquist, L., Axelson, H., Borg, A., and Pahlman, S. (2004). Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. *Experimental Cell Research* **295**, 469-487.
314. Kimura, S., Kitadai, Y., Tanaka, S., Kuwai, T., Hihara, J., Yoshida, K., Toge, T., and Chayama, K. (2004). Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. *Eur J Cancer* **40**, 1904-1912.

315. Buchler, P., Reber, H. A., Lavey, R. S., Tomlinson, J., Buchler, M. W., Friess, H., and Hines, O. J. (2004). Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. *J Surg.Res* **120**, 295-303.
316. Beasley, N. J., Leek, R., Alam, M., Turley, H., Cox, G. J., Gatter, K., Millard, P., Fuggle, S., and Harris, A. L. (2002). Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. *Cancer Res* **62**, 2493-2497.
317. Onita, T., Ji, P. G., Xuan, J. W., Sakai, H., Kanetake, H., Maxwell, P. H., Fong, G. H., Gabril, M. Y., Moussa, M., and Chin, J. L. (2002). Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. *Clin.Cancer Res* **8**, 471-480.
318. Piret, J. P., Lecocq, C., Toffoli, S., Ninane, N., Raes, M., and Michiels, C. (2004). Hypoxia and CoCl₂ protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. *Experimental Cell Research* **295**, 340-349.
319. Weinmann, M., Jendrossek, V., Handrick, R., Guner, D., Goecke, B., and Belka, C. (2004). Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner. *Oncogene* **23**, 3757-3769.
320. Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H. P., Johnson, R. S., and Bergers, G. (2003). The hypoxic response of tumors is dependent on their microenvironment. *Cancer Cell* **4**, 133-146.
321. Teicher, B. A. (1994). Hypoxia and drug resistance. *Cancer Metastasis Rev* **13**, 139-168.
322. Moeller, B. J., Cao, Y., Li, C. Y., and Dewhirst, M. W. (2004). Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. *Cancer Cell* **5**, 429-441.
323. Xia, S., Yu, S. Y., Yuan, X. L., and Xu, S. P. (2004). Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line. *Zhonghua Yi.Xue.Za Zhi* **84**, 663-666.
324. Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., and Dive, C. (2004). Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. *Mol Cell Biol* **24**, 2875-2889.
325. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. *Int J Radiat.Oncol Biol Phys.* **38**, 285-289.
326. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., Gatter, K. C., and Harris, A. L. (2002). Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. *Int.J.Radiat.Oncol.Biol.Phys.* **53**, 1192-1202.
327. Brown, L. M., Cowen, R. L., Debray, C., Eustace, A., Erler, J. T., Sheppard, F. C., Parker, C. A., Stratford, I. J., and Williams, K. J. (2005). REVERSING HYPOXIC CELL CHEMORESISTANCE IN VITRO USING GENETIC AND SMALL MOLECULE APPROACHES TARGETING HYPOXIA INDUCIBLE FACTOR-1. *Mol Pharmacol*.
328. Rak, J. and Yu, J. L. (2004). Oncogenes and tumor angiogenesis: The question of vascular 'supply' and vascular 'demand'. *Seminars in Cancer Biology* **14**, 93-104.

329. Kaanders, J. H., Pop, L. A., Marres, H. A., Bruaset, I., van den Hoogen, F. J., Merkx, M. A., and van der Kogel, A. J. (2002). ARCON: experience in 215 patients with advanced head-and-neck cancer. *Int J Radiat. Oncol Biol Phys* **52**, 769-778.
330. Brown, J. M. and Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment. *Nat.Rev.Cancer* **4**, 437-447.
331. Brown, J. M. and Lemmon, M. J. (1990). Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. *Cancer Res* **50** , 7745-7749.
332. Lunt, S. J., Telfer, B. A., Fitzmaurice, R. J., Stratford, I. J., and Williams, K. J. (2005). Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. *Clin Cancer Res* **11**, 4212-4216.
333. Rischin, D., Peters, L., Hicks, R., Hughes, P., Fisher, R., Hart, R., Sexton, M., D'Costa, I., and von Roemeling, R. (2001). Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. *J Clin Oncol* **19**, 535-542.
334. Dorie, M. J. and Brown, J. M. (1993). Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. *Cancer Res* **53**, 4633-4636.
335. Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L., Penniment, M., Corry, J., Lamb, D., and McClure, B. (2005). Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). *J Clin Oncol* **23**, 79-87.
336. Patterson, L. H. (2002). Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. *Drug Metab Rev* **34**, 581-592.
337. Gallagher, R., Hughes, C. M., Murray, M. M., Friery, O. P., Patterson, L. H., Hirst, D. G., and McKeown, S. R. (2001). The chemopotential of cisplatin by the novel bioreductive drug AQ4N. *Br J Cancer* **85**, 625-629.
338. Loadman, P. M., Swaine, D. J., Bibby, M. C., Welham, K. J., and Patterson, L. H. (2001). A preclinical pharmacokinetic study of the bioreductive drug AQ4N. *Drug Metab Dispos* **29**, 422-426.
339. Wilson, W. R., Tercel, M., Anderson, R. F., and Denny, W. A. (1998). Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. *Anticancer Drug Des* **13**, 663-685.
340. Dai, S., Huang, M. L., Hsu, C. Y., and Chao, K. S. C. (2003). Inhibition of hypoxia inducible factor 1[alpha] causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. *International Journal of Radiation Oncology*Biological*Physics* **55**, 1027-1036.
341. Sun, X. Y., Meng, F. Q., Jiang, H. C., Qiao, H. Q., and Li, W. (2005). [Antisense hypoxia inducible factor-1alpha and B7-1 combination gene therapy for mouse lymphoma.]. *Zhonghua Zhong.Liu Za Zhi* **27**, 404-407.
342. Mizuno, T., Nagao, M., Yamada, Y., Narikiyo, M., Ueno, M., Miyagishi, M., Taira, K., and Nakajima, Y. (2005). Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. *Cancer Gene Ther* .
343. Harada, H., Hiraoka, M., and Kizaka-Kondoh, S. (2002). Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. *Cancer Res* **62**, 2013-2018.
344. Wang, D., Ruan, H., Hu, L., Lamborn, K. R., Kong, E. L., Rehemtulla, A., and Deen, D. F. (2005). Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. *Cancer Gene Ther* **12**, 276-283.

345. Post, D. E. and Van Meir, E. G. (2003). A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. *Oncogene* **22**, 2065-2072.
346. Pipiya, T., Sauthoff, H., Huang, Y. Q., Chang, B., Cheng, J., Heitner, S., Chen, S., Rom, W. N., and Hay, J. G. (2005). Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. *Gene Ther* **12**, 911-917.
347. Shen, B. H. and Hermiston, T. W. (2005). Effect of hypoxia on Ad5 infection, transgene expression and replication. *Gene Ther* **12**, 902-910.
348. Pin, R. H., Reinblatt, M., Bowers, W. J., Federoff, H. J., and Fong, Y. (2004). Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. *J Gastrointest. Surg.* **8**, 812-822.
349. Fox, M. E., Lemmon, M. J., Mauchline, M. L., Davis, T. O., Giaccia, A. J., Minton, N. P., and Brown, J. M. (1996). Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. *Gene Ther* **3**, 173-178.
350. Yazawa, K., Fujimori, M., Nakamura, T., Sasaki, T., Amano, J., Kano, Y., and Taniguchi, S. (2001). Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. *Breast Cancer Res Treat.* **66**, 165-170.
351. Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., and Melillo, G. (2004). Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1: Mechanism and Therapeutic Implications. *Cancer Res* **64**, 1475-1482.
352. Lund, E. L., Hansen, L. T., and Kristjansen, P. E. (2005). Augmenting tumor sensitivity to topotecan by transient hypoxia. *Cancer Chemother. Pharmacol.*
353. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., and Powis, G. (2004). Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. *Mol Cancer Ther* **3**, 233-244.
354. Jones, M. K., Szabo, I. L., Kawanaka, H., Husain, S. S., and Tarnawski, A. S. (2002). von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. *FASEB J.* **16**, 264-266.
355. Mabejesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W., and Zhong, H. (2002). Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteasome pathway in prostate cancer cells. *Cancer Res* **62**, 2478-2482.
356. Ibrahim, N. O., Hahn, T., Franke, C., Stiehl, D. P., Wirthner, R., Wenger, R. H., and Katschinski, D. M. (2005). Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. *Cancer Res* **65**, 11094-11100.
357. Erez, N., Milyavsky, M., Eilam, R., Shats, I., Goldfinger, N., and Rotter, V. (2003). Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. *Cancer Res* **63**, 8777-8783.
358. D'Angelo, G., Duplan, E., Vigne, P., and Frelin, C. (2003). Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation. *J Biol Chem.* **278**, 15406-15411.
359. Temes, E., Martin-Puig, S., Acosta-Iborra, B., Castellanos, M. C., Feijoo-Cuaresma, M., Olmos, G., Aragones, J., and Landazuri, M. O. (2005). Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. *J Biol Chem.* **280**, 24238-24244.
360. Mie, L. Y., Kim, S. H., Kim, H. S., Jin, S. M., Nakajima, H., Jeong, K. H., and Kim, K. W. (2003). Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. *Biochem Biophys. Res Commun.* **300**, 241-246.

361. Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., Moon, E. J., Kim, H. S., Lee, S. K., Chung, H. Y., Kim, C. W., and Kim, K. W. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. *Nat.Med.* **7**, 437-443.
362. Welsh, S. J., Williams, R. R., Birmingham, A., Newman, D. J., Kirkpatrick, D. L., and Powis, G. (2003). The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1{alpha} and Vascular Endothelial Growth Factor Formation. *Mol Cancer Ther* **2**, 235.
363. Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. (1997). Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. *Am J Pathol* **151**, 1523-1530.
364. Chang, H., Shyu, K. G., Lee, C. C., Tsai, S. C., Wang, B. W., Hsien, L. Y., and Lin, S. (2003). GL331 inhibits HIF-1alpha expression in a lung cancer model. *Biochem Biophys.Res Commun.* **302**, 95-100.
365. Mabejesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., and Giannakakou, P. (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. *Cancer Cell* **3**, 363-375.
366. Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M., and Van Waes, C. (2004). 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. *Clin Cancer Res* **10**, 8665-8673.
367. Cao, Z., Fang, J., Xia, C., Shi, X., and Jiang, B. H. (2004). trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. *Clin Cancer Res* **10**, 5253-5263.
368. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S., and Park, J. W. (2003). YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1. *JNCI Cancer Spectrum* **95**, 516-525.
369. Luwor, R. B., Lu, Y., Li, X., Mendelsohn, J., and Fan, Z. (2005). The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. *Oncogene* **24**, 4433-4441.
370. Li, L., Lin, X., Staver, M., Shoemaker, A., Semizarov, D., Fesik, S. W., and Shen, Y. (2005). Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. *Cancer Res* **65**, 7249-7258.
371. Yoshimura, H., Dhar, D. K., Kohno, H., Kubota, H., Fujii, T., Ueda, S., Kinugasa, S., Tachibana, M., and Nagasue, N. (2004). Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. *Clin Cancer Res* **10**, 8554-8560.
372. Covello, K. L., Simon, M. C., and Keith, B. (2005). Targeted Replacement of Hypoxia-Inducible Factor-1{alpha} by a Hypoxia-Inducible Factor-2{alpha} Knock-in Allele Promotes Tumor Growth. *Cancer Res* **65**, 2277-2286.
373. Acker, T., Diez-Juan, A., Aragonés, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D., Moreno-Murciano, M. P., Herbert, J. M., Burger, A., Riedel, J., Elvert, G., Flamme, I., Maxwell, P. H., Collen, D., Dewerchin, M., Jain, R. K., Plate, K. H., and Carmeliet, P. (2005). Genetic evidence for a tumor suppressor role of HIF-2alpha. *Cancer Cell* **8**, 131-141.

374. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. (2002). Effect of p53 status on tumor response to antiangiogenic therapy. *Science* **295**, 1526-1528.
375. Allen, C. B., Schneider, B. K., and White, C. W. (2001). Limitations to oxygen diffusion and equilibration in in vitro cell exposure systems in hyperoxia and hypoxia. *Am.J.Physiol Lung Cell Mol Physiol* **281**, L1021-L1027.
376. Kotelevets, L., van Hengel, J., Bruyneel, E., Mareel, M., van Roy, F., and Chastre, E. (2001). The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. *J.Cell Biol.* **155**, 1129-1136.
377. Subramanian, A. and Miller, D. M. (2000). Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. *J Biol Chem.* **275**, 5958-5965.
378. Sasaki, Y., Ohsawa, K., Kanazawa, H., Kohsaka, S., and Imai, Y. (2001). Iba1 is an actin-cross-linking protein in macrophages/microglia. *Biochem Biophys.Res Commun.* **286** , 292-297.
379. Mottet, D., Michel, G., Renard, P., Ninane, N., Raes, M., and Michiels, C. (2002). ERK and calcium in activation of HIF-1. *Ann.N.Y.Acad.Sci.* **973**, 448-453.
380. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio, P. M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell* **3**, 347-361.
381. Hayano, T. and Kikuchi, M. (1995). Cloning and sequencing of the cDNA encoding human P5. *Gene* **164**, 377-378.
382. Tanaka, S., Uehara, T., and Nomura, Y. (2000). Up-regulation of Protein-disulfide Isomerase in Response to Hypoxia/Brain Ischemia and Its Protective Effect against Apoptotic Cell Death. *J.Biol.Chem.* **275**, 10388-10393.
383. Sakai, J., Ishikawa, H., Kojima, S., Satoh, H., Yamamoto, S., and Kanaoka, M. (2003). Proteomic analysis of rat heart in ischemia and ischemia-reperfusion using fluorescence two-dimensional difference gel electrophoresis. *Proteomics* **3**, 1318-1324.
384. Sullivan, D. C., Huminiecki, L., Moore, J. W., Boyle, J. J., Poulosom, R., Creamer, D., Barker, J., and Bicknell, R. (2003). EndoPDI, a Novel Protein-disulfide Isomerase-like Protein That Is Preferentially Expressed in Endothelial Cells Acts as a Stress Survival Factor. *J.Biol.Chem.* **278**, 47079-47088.
385. Kivirikko, K. I. and Myllyharju, J. (1998). Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. *Matrix Biol.* **16**, 357-368.
386. Lee, K. A., Shim, J. H., Kho, C. W., Park, S. G., Park, B. C., Kim, J. W., Lim, J. S., Choe, Y. K., Paik, S. G., and Yoon, D. Y. (2004). Protein profiling and identification of modulators regulated by the E7 oncogene in the C33A cell line by proteomics and genomics. *Proteomics* **4**, 839-848.
387. Ryu, J. W., Kim, H. J., Lee, Y. S., Myong, N. H., Hwang, C. H., Lee, G. S., and Yom, H. C. (2003). The proteomics approach to find biomarkers in gastric cancer. *J Korean Med Sci* **18**, 505-509.
388. Chahed, K., Kabbage, M., Ehret-Sabatier, L., Lemaitre-Guillier, C., Remadi, S., Hoebeke, J., and Chouchane, L. (2005). Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. *Int J Oncol* **27**, 1425-1431.
389. Shen, J., Person, M. D., Zhu, J., Abbruzzese, J. L., and Li, D. (2004). Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. *Cancer Res* **64**, 9018-9026.

390. Stierum, R., Gaspari, M., Dommels, Y., Ouatas, T., Pluk, H., Jespersen, S., Vogels, J., Verhoeckx, K., Groten, J., and Ommen, B. v. (2003). Proteome analysis reveals novel proteins associated with proliferation and differentiation of the colorectal cancer cell line Caco-2. *Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics* **1650**, 73-91.
391. Siddiq, A., Ayoub, I. A., Chavez, J. C., Aminova, L., Shah, S., LaManna, J. C., Patton, S. M., Connor, J. R., Cherny, R. A., Volitakis, I., Bush, A., Langsetmo, I., Seeley, T., Gunzler, V., and Ratan, R. R. (2005). HIF prolyl 4-hydroxylase inhibition: A target for neuroprotection in the central nervous system. *J Biol Chem*.
392. Ghosh, A. K., Steele, R., and Ray, R. B. (2005). c-myc Promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway. *J Biol Chem*. **280**, 14325-14330.
393. Fan, X., Solomon, H., Schwarz, K., Kew, M. C., Ray, R. B., and Di Bisceglie, A. M. (2001). Expression of c-myc promoter binding protein (MBP-1), a novel eukaryotic repressor gene, in cirrhosis and human hepatocellular carcinoma. *Dig.Dis.Sci* **46**, 563-566.
394. Gerbitz, K. D., Summer, J., Schumacher, I., Arnold, H., Kraft, A., and Mross, K. (1986). Enolase isoenzymes as tumour markers. *J Clin Chem.Clin Biochem* **24**, 1009-1016.
395. Chang, Y. S., Wu, W., Walsh, G., Hong, W. K., and Mao, L. (2003). Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. *Clin Cancer Res* **9**, 3641-3644.
396. Wolf, D. H. and Hilt, W. (2004). The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. *Biochim.Biophys.Acta* **1695**, 19-31.
397. Brahimi-Horn, C. and Pouyssegur, J. (2005). When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy. *Critical Reviews in Oncology/Hematology* **53**, 115-123.
398. Mendoza, F. J., Espino, P. S., Cann, K. L., Bristow, N., McCrea, K., and Los, M. (2005). Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets. *Arch.Immunol Ther Exp (Warsz.)* **53**, 47-60.
399. Okamura, T., Taniguchi, S., Ohkura, T., Yoshida, A., Shimizu, H., Sakai, M., Maeta, H., Fukui, H., Ueta, Y., Hisatome, I., and Shigemasa, C. (2003). Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. *J Clin Endocrinol Metab* **88**, 1374-1383.
400. Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S., Shimbara, N., and Ichihara, A. (1991). Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. *Cancer Res* **51**, 6677-6685.
401. Khal, J., Hine, A. V., Fearon, K. C., Dejong, C. H., and Tisdale, M. J. (2005). Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. *Int J Biochem Cell Biol* **37**, 2196-2206.
402. Smith, H. J., Wyke, S. M., and Tisdale, M. J. (2004). Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate. *Cancer Res* **64**, 8731-8735.
403. Hodgkinson, J. L., Peters, C., Kuznetsov, S. A., and Steffen, W. (2005). Three-dimensional reconstruction of the dynactin complex by single-particle image analysis. *Proc Natl Acad Sci U S A* **102**, 3667-3672.
404. Bhattacharya, N., Wang, Z., Davitt, C., McKenzie, I. F., Xing, P. X., and Magnuson, N. S. (2002). Pim-1 associates with protein complexes necessary for mitosis. *Chromosoma* **111**, 80-95.
405. Dammermann, A. and Merdes, A. (2002). Assembly of centrosomal proteins and microtubule organization depends on PCM-1. *J Cell Biol* **159**, 255-266.

406. Corvi, R., Berger, N., Balczon, R., and Romeo, G. (2000). RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma. *Oncogene* **19**, 4236-4242.
407. Sun, Q. Y. and Schatten, H. (2006). Role of NuMA in vertebrate cells: review of an intriguing multifunctional protein. *Front Biosci.* **11**, 1137-1146.
408. Tong, X., Xie, D., Roth, W., Reed, J., and Koeffler, H. P. (2003). NADE (p75NTR-associated cell death executor) suppresses cellular growth in vivo. *Int J Oncol* **22**, 1357-1362.
409. Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. (2004). Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. *J Biol Chem.* **279**, 22483-22489.
410. Burkhardt, J. K., Echeverri, C. J., Nilsson, T., and Vallee, R. B. (1997). Overexpression of the dynamitin (p50) subunit of the dynactin complex disrupts dynein-dependent maintenance of membrane organelle distribution. *J Cell Biol* **139**, 469-484.
411. Kondratova, A. A., Neznanov, N., Kondratov, R. V., and Gudkov, A. V. (2005). Poliovirus Protein 3A Binds and Inactivates LIS1, Causing Block of Membrane Protein Trafficking and Dereglulation of Cell Division. *Cell Cycle* **4**.
412. Valetti, C., Wetzel, D. M., Schrader, M., Hasbani, M. J., Gill, S. R., Kreis, T. E., and Schroer, T. A. (1999). Role of dynactin in endocytic traffic: effects of dynamitin overexpression and colocalization with CLIP-170. *Mol Biol Cell* **10**, 4107-4120.
413. Clark, I. B. and Meyer, D. I. (1999). Overexpression of normal and mutant Arp1alpha (centractin) differentially affects microtubule organization during mitosis and interphase. *J Cell Sci* **112 (Pt 20)**, 3507-3518.
414. Deininger, M. H., Meyermann, R., and Schluesener, H. J. (2002). The allograft inflammatory factor-1 family of proteins. *FEBS Lett.* **514**, 115-121.
415. Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., and Kohsaka, S. (1998). Microglia-specific localisation of a novel calcium binding protein, Iba1. *Brain Res Mol Brain Res* **57**, 1-9.
416. Ito, D., Tanaka, K., Suzuki, S., Dembo, T., and Fukuuchi, Y. (2001). Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. *Stroke* **32**, 1208-1215.
417. Ohsawa, K., Imai, Y., Kanazawa, H., Sasaki, Y., and Kohsaka, S. (2000). Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. *J Cell Sci.* **113 (Pt 17)**, 3073-3084.
418. Imai, Y. and Kohsaka, S. (2002). Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. *Glia* **40**, 164-174.
419. Ohsawa, K., Imai, Y., Sasaki, Y., and Kohsaka, S. (2004). Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. *J Neurochem.* **88**, 844-856.
420. Smith, I. F., Boyle, J. P., Vaughan, P. F., Pearson, H. A., and Peers, C. (2001). Effects of chronic hypoxia on Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells. *J. Neurochem.* **79**, 877-884.
421. Berchner-Pfannschmidt, U., Petrat, F., Doege, K., Trinidad, B., Freitag, P., Metzen, E., de Groot, H., and Fandrey, J. (2004). Chelation of Cellular Calcium Modulates Hypoxia-inducible Gene Expression through Activation of Hypoxia-inducible Factor-1{alpha}. *J. Biol. Chem.* **279**, 44976-44986.
422. Del Toro, R., Levitsky, K. L., Lopez-Barneo, J., and Chiara, M. D. (2003). Induction of T-type Calcium Channel Gene Expression by Chronic Hypoxia. *J. Biol. Chem.* **278**, 22316-22324.

423. Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2004). Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. *Am J Physiol Renal Physiol* **286**, F338-F348.
424. Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2003). HIF-1{alpha} mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. *J Cell Sci* **116**, 2247-2260.
425. Hirota, K. and Semenza, G. L. (2001). Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1. *J.Biol.Chem.* **276**, 21166-21172.
426. Xue, Y., Bi, F., Zhang, X., Pan, Y., Liu, N., Zheng, Y., and Fan, D. (2004). Inhibition of endothelial cell proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells. *Biochem Biophys.Res Commun.* **320**, 1309-1315.
427. Udho, E., Tedesco, V. C., Zygmunt, A., and Krucher, N. A. (2002). PNUTS (phosphatase nuclear targeting subunit) inhibits retinoblastoma-directed PP1 activity. *Biochem Biophys.Res Commun.* **297**, 463-467.
428. Chen, J., Cohn, J. A., and Mandel, L. J. (1995). Dephosphorylation of ezrin as an early event in renal microvillar breakdown and anoxic injury. *Proc Natl Acad Sci U S A* **92**, 7495-7499.
429. Noda, Y., Horikawa, S., Katayama, Y., and Sasaki, S. (2005). Identification of a multiprotein "motor" complex binding to water channel aquaporin-2. *Biochem Biophys.Res Commun.* **330**, 1041-1047.
430. Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M., and Verkman, A. S. (2005). Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. *Nature* **434**, 786-792.
431. Saadoun, S., Papadopoulos, M. C., Watanabe, H., Yan, D., Manley, G. T., and Verkman, A. S. (2005). Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. *J Cell Sci* **118**, 5691-5698.